11.20

107.02% 5.79

Replimune Group Inc (REPL)

Overview News Price History Option Chain Financials Discussions Forecast

Replimune Group Inc stock is traded at $11.20, with a volume of 33.46M. It is up +107.02% in the last 24 hours and up +1.17% over the past month. Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.

Previous Close:

$5.41

Open:

$11.379

24h Volume:

33.46M

Relative Volume:

5.78

Market Cap:

$940.19M

Revenue:

Net Income/Loss:

$-313.94M

P/E Ratio:

-3.1945

EPS:

-3.506

Net Cash Flow:

$-284.57M

1W Performance:

+15.46%

1M Performance:

+1.17%

6M Performance:

+59.32%

1Y Performance:

+59.32%

1-Day Range:

$9.43

$12.50

1-Week Range:

$4.7648

$12.50

52-Week Range:

$1.50

$12.50

Replimune Group Inc Stock (REPL) Company Profile

Name

Replimune Group Inc

Sector

Healthcare (1079)

Industry

Biotechnology (598)

Phone

(781) 222-9600

Address

500 UNICORN PARK, WOBURN, MA

Employee

465

Twitter

@Replimune

Next Earnings Date

2026-08-06

Latest SEC Filings

REPL's Discussions on Twitter

Compare REPL vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
REPL Replimune Group Inc	11.20	724.45M	0	-313.94M	-284.57M	-3.506
VRTX Vertex Pharmaceuticals Inc	477.10	121.57B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	762.63	69.95B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	853.82	55.61B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	187.53	39.98B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	316.01	33.81B	5.76B	514.49M	1.10B	4.4813

Replimune Group Inc Stock (REPL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Downgrade	BMO Capital Markets	Market Perform → Underperform
Apr-13-26	Downgrade	H.C. Wainwright	Buy → Sell
Apr-13-26	Downgrade	JP Morgan	Neutral → Underweight
Apr-13-26	Downgrade	Jefferies	Buy → Hold
Apr-13-26	Downgrade	Leerink Partners	Outperform → Market Perform
Apr-13-26	Downgrade	Wedbush	Outperform → Neutral
Apr-10-26	Downgrade	Piper Sandler	Overweight → Neutral
Nov-03-25	Upgrade	BMO Capital Markets	Underperform → Market Perform
Oct-27-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-20-25	Upgrade	JP Morgan	Underweight → Neutral
Oct-20-25	Upgrade	Leerink Partners	Market Perform → Outperform
Oct-20-25	Upgrade	Piper Sandler	Neutral → Overweight
Oct-20-25	Upgrade	Wedbush	Neutral → Outperform
Sep-19-25	Downgrade	JP Morgan	Neutral → Underweight
Jul-30-25	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Jul-23-25	Downgrade	BMO Capital Markets	Outperform → Underperform
Jul-23-25	Downgrade	Barclays	Overweight → Equal Weight
Jul-23-25	Downgrade	H.C. Wainwright	Buy → Neutral
Jul-22-25	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-25	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-22-25	Downgrade	Piper Sandler	Overweight → Neutral
Jul-22-25	Downgrade	Wedbush	Outperform → Neutral
Jun-20-25	Initiated	Cantor Fitzgerald	Overweight
Aug-28-24	Initiated	ROTH MKM	Buy
Apr-17-23	Resumed	Piper Sandler	Overweight
Nov-19-21	Initiated	Piper Sandler	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-17-20	Initiated	BTIG Research	Buy
Nov-02-20	Initiated	Jefferies	Buy
Oct-15-20	Upgrade	H.C. Wainwright	Neutral → Buy
Jul-01-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-05-20	Initiated	Barclays	Overweight
Sep-04-19	Initiated	ROTH Capital	Buy
Jul-23-19	Initiated	Chardan Capital Markets	Buy
Jul-12-19	Upgrade	JP Morgan	Neutral → Overweight
Jul-08-19	Initiated	H.C. Wainwright	Buy
Apr-25-19	Initiated	Wedbush	Outperform
Jan-23-19	Downgrade	JP Morgan	Overweight → Neutral
Aug-14-18	Initiated	JP Morgan	Overweight
Aug-14-18	Initiated	Leerink Partners	Outperform

View All

Replimune Group Inc Stock (REPL) Latest News

Jul 28, 2026

Wedbush Weighs FDA Advisory Committee Vote on REPL's RP1 Amid Mi - GuruFocus

Jul 28, 2026

FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Yahoo Finance

Jul 28, 2026

US FDA staff cast doubt on Replimune cancer drug’s benefit; shares slide - 1470 & 100.3 WMBD

Jul 28, 2026

Replimune (REPL) Slumps As Losses Mount And Legal Scrutiny Grows - StocksToTrade

Jul 28, 2026

Replimune joins Capricor in post-briefing doc drop (REPL:NASDAQ) - Seeking Alpha

Jul 28, 2026

US FDA staff raise efficacy concerns on Replimune's skin cancer drug ahead of meeting - Reuters

Jul 28, 2026

Replimune stock tumbles 20% after FDA raises efficacy concerns By Investing.com - Investing.com Nigeria

Jul 28, 2026

Jul 27, 2026